Drugs / hu14.18-Interleukin-2 fusion protein
hu14.18-Interleukin-2 fusion protein
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00082758 | Aug 2005 → Feb 2008 | neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hu14.18-Interleukin-2 fusion protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00082758 ↗ |
| Known as | hu14.18-IL2 | “The hu14.18-IL2 fusion protein consists of interleukin-2 molecularly linked to a humanized monoclonal antibody that recognizes the GD2 disialoganglioside expressed on...” PMID 20921469 ↗ Oct 2010 |
| Known as | IMMUNOCYTOKINE HU14.18-IL2 FUSION PROTEIN | “IMMUNOCYTOKINE HU14.18-IL2 FUSION PROTEIN” NCT00082758 ↗ |
| Modality | Protein / enzyme biologic | “The hu14.18-IL2 fusion protein consists of interleukin-2 molecularly linked to a humanized monoclonal antibody that recognizes the GD2 disialoganglioside expressed on...” PMID 20921469 ↗ Oct 2010 |
| Route | Intravenous | “Hu14.18-IL2 was given intravenously (12 mg/m(2)/daily) for 3 days every 4 weeks” PMID 20921469 ↗ Oct 2010 |